Goodsurance
ES

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

By the Goodsurance editorial teamOctober 30, 2026

A KFF analysis published October 30, 2026 projects that the average monthly premium for Medicare stand-alone prescription drug plans will climb 50 percent in 2027, from 34 dollars to 51 dollars, for enrollees who do not switch plans during the current open enrollment period.

Premium costs vary widely across plans. The lowest-premium national stand-alone drug plan carries a monthly charge of 6.50 dollars, while the most expensive runs 204.50 dollars per month. For context, the average monthly charge for drug coverage bundled inside a Medicare Advantage plan is projected at just 9 dollars in 2027, making stand-alone plan premiums more than five times higher on average.

Average Medicare Part D stand-alone premium projected to jump 50 percent to 51 dollars a month in 2027 for enrollees who do not switch plans before December 7.

Deductibles are also increasing. The average deductible for stand-alone drug plans is projected at 643 dollars in 2027, up from 540 dollars in 2026. The maximum allowable Part D deductible rises to 700 dollars, from 615 dollars. Nearly all stand-alone drug plan enrollees, 99.8 percent, will face a deductible next year.

About 4 million enrollees currently in zero-premium stand-alone drug plans will face new monthly charges in 2027, as no zero-premium options will be available for beneficiaries who do not qualify for low-income subsidies.

Medicare open enrollment runs through December 7. During this window, beneficiaries can compare plan options at medicare.gov.

In plain words

A report from KFF looks at what Medicare drug plan costs will be in 2027. If you have a stand-alone Part D drug plan and you do not switch it, your average monthly premium could go up 50 percent. That means going from 34 dollars a month to 51 dollars a month.

The amount you pay before your plan starts helping, called the deductible, is going up too. The average deductible will be 643 dollars in 2027. This year it is 540 dollars.

About 4 million people who currently pay nothing each month for their plan will face a new premium charge in 2027, because no free plans will be available for most enrollees.

Medicare open enrollment is open right now and goes until December 7. That is the time to look at your plan options and switch if you find one that costs less at medicare.gov.

Source: KFF
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Part D Rarely Covers the OTC Naloxone Nasal Spray. Medicaid Usually Does.

A new Government Accountability Office report finds that most Part D plans stopped covering the over-the-counter naloxone nasal spray after it no longer required a prescription, while Medicaid covers the same product at little or no cost to enrollees.

November 16, 2026

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Study: Medicare Drug Price Negotiations Cut Costs for Most Enrollees, but Not for Those Already Hitting the Annual Spending Limit

A research letter in Annals of Internal Medicine finds that patients on six of the first ten negotiated Part D drugs saw out-of-pocket costs fall 26 to 49 percent, while patients on the three highest-priced negotiated drugs saw no additional benefit because they were already reaching the annual cap.

October 24, 2026